RxDoctor Payments Data

Lee Brock, MD

Anesthesiology · Dallas, TXNPI 1336126036

Payments from drug & device makers

$4,507in general payments, 2019–2025

Across 292 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$941
  • Abbott$363
  • AbbVie$352
  • Daiichi Sankyo Inc.$325
  • Collegium Pharmaceutical, Inc.$309
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$264
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,501100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,507 in reported general payments places this provider in the 95th percentile of 3,899 anesthesiology providers in Texas.

See all anesthesiology providers in Texas

Medicare billing

Part B allowed, 2024
$84,840
Medicare patients
263
Services billed
2,887

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide27$63,005
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,628$57,319
Relafen DsNabumetone16$51,675
MovantikNaloxegol Oxalate90$47,770
Xtampza ErOxycodone Myristate104$46,169
RayosPrednisone13$36,420
OxycontinOxycodone Hcl65$36,291
BelbucaBuprenorphine Hcl33$32,709
Nurtec OdtRimegepant Sulfate11$20,417
Buprenorphine71$20,387
UbrelvyUbrogepant13$19,339
Fentanyl173$18,077
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen387$17,302
Diclofenac Sodium40$15,981
SymproicNaldemedine Tosylate21$9,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$309$78,879137 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$264$63,00527 claims
Redhill Biopharma Inc.Movantik$16$47,77090 claims
AmgenRayos$87$36,42013 claims
PfizerNurtec Odt$147$20,41711 claims
AbbVieUbrelvy$352$19,33913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,899 anesthesiology providers in Texas.

Other anesthesiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →